Sector Expert: Scott Henry

ROTH Capital Partners

Image: Scott Henry

Scott Henry is the head of healthcare research and a senior research analyst with ROTH Capital Partners, covering the specialty pharmaceutical sector. He came to ROTH Capital from OppenheimerFunds, where he led coverage of the U.S. pharmaceutical sector. He has also been affiliated with Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. His coverage universe has included specialty pharmaceuticals, large-cap pharmaceuticals, biotech and selective medical device names. He has 12 years of sellside experience. Henry was ranked #2 in The Wall Street Journal's "Best on the Street" stock-picking survey in 2010 and #3 on the Forbes/Zacks Investment Research "Best Analysts" list for the Drugs category in 2010. His investment views have been cited in The Wall Street Journal and The New York Times and he has made frequent appearances on CNBC, CBS Marketwatch, and Bloomberg. Henry attended the University of Rhode Island and received a master's degree in business administration with distinction from Cornell University.



Recent Interviews

Six Opportunities in the Specialty Pharmaceutical Space: Scott Henry (11/7/13)

The specialty pharmaceuticals universe encompasses a variety of technologies, among them innovative drug delivery systems and unique pain management and orphan disease treatments. In this interview with The Life Sciences Report, Scott Henry of ROTH Capital Markets touts the value of "sound business models" in the specialty pharma space, and names six companies with interesting prospects and/or stock-moving catalysts on the horizon.

Recent Quotes

"CRMD reported earnings within the range of expectations."

— Scott Henry, ROTH Capital Partners (11/16/15)
more >

— Scott Henry, ROTH Capital Partners (10/29/15)
more >

"BDSI announced positive top-line results from its Phase 3 study."

— Scott Henry, ROTH Capital Partners (7/7/14)
more >

"BDSI announced that Bunavail has been approved."

— Scott Henry, ROTH Capital Partners (6/9/14)
more >

"We view Bunavail as the most undervalued asset at BDSI."

— Scott Henry, ROTH Capital Partners (3/17/14)
more >

"CPRX's Firdapse program remains on track for a Q1/15 filing."

— Scott Henry, ROTH Capital Partners (1/6/14)
more >

"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved."

The Life Sciences Report Interview with Scott Henry (11/7/13)
more >

"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines."

The Life Sciences Report Interview with Scott Henry (11/7/13)
more >



Due to permission requirements, not all quotes are shown.